Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Nurix Therapeutics reports Thursday with short sellers maintaining a meaningful but slightly retreating position, while options positioning has drifted more cautious and the stock has lost ground through October.
Short interest is elevated at 17.2% of the free float, roughly 17.5 million shares. That is the headline bearish signal, though the direction has turned modestly friendlier for longs: short interest fell about 3.7% over the past week and is effectively flat over the past month. The borrow market tells a similar story of reduced urgency. Availability is exceptionally loose at 2,229%, meaning there are more than 22 shares available to lend for every one already borrowed, and borrowing costs are low at 0.55% annualised. Short sellers face no structural squeeze pressure here. Options are a touch more defensive than usual: the put/call ratio of 0.93 is running above its 20-day average of 0.88, though the z-score of under one standard deviation means the skew is noticeable rather than alarming. The stock itself has dropped 11.7% over the past month and 3.1% on the week to close at $22.16, compressing the gap to analyst targets.
The Street remains constructive, with all seven tracked analysts carrying buy-equivalent ratings and a consensus price target near $34.30, implying roughly 55% upside from current levels. The target-price trajectory has moved higher, not lower: Morgan Stanley raised its target to $38 in late July, and RBC Capital lifted its own to $36 in August. Bulls centre the thesis on bexobrutideg's CLL data, the protein degradation platform's breadth into hematologic and autoimmune indications, and a collaboration roster that includes Roche, Sanofi, Gilead and Pfizer. Pro forma cash in excess of $1 billion is cited as runway support. Bears counter that the entire valuation rests on a narrow clinical pipeline with no approved products. If bexobrutideg disappoints on durability or safety, the argument goes, the shares revert toward net cash and the pipeline carries little residual value. Competition in STAT6 is also building, with several inhibitors already in the clinic.
The ownership picture adds context to the conviction on the long side. Specialist healthcare funds have been building. Deep Track Capital added more than 2.2 million shares in the quarter to June, Rubric Capital Management added nearly 4.8 million to reach 7.2 million shares, and Perceptive Advisors reported a fresh 5.3% stake as of mid-September. Redmile trimmed its position but remains a top holder. All activist filings on record are passive 13G filings, with no Schedule 13D holder. Recent insider transactions are routine 10b5-1 plan exercises and same-day sales by the Chief Legal Officer and Chief Scientific Officer, not discretionary conviction trades. Wikipedia retail attention has spiked to a z-score of 3.8 relative to the prior 90 days, suggesting elevated public interest into the event.
Past earnings reactions for NRIX have been asymmetric. The July 2026 quarterly print produced a 5.1% one-day drop followed by a further decline over five days. The May 2026 report fell 3.1% on the day but recovered sharply over the week. Thursday's print will test whether the clinical update on bexobrutideg and the STAT6 and IRAK4 programs can narrow the gap between where the stock trades and where a broadly bullish analyst community thinks it belongs.
See the live data behind this article on ORTEX.
Open NRIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
